Hemispherx BioPharma, Inc (NYSE:HEB) saw a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 1,083,842 shares, a growth of 3.8% from the October 13th total of 1,044,475 shares. Based on an average trading volume of 150,622 shares, the days-to-cover ratio is currently 7.2 days. Approximately 3.6% of the company’s stock are sold short.
Shares of Hemispherx BioPharma (NYSE HEB) opened at $0.32 on Monday. Hemispherx BioPharma has a 1-year low of $0.30 and a 1-year high of $0.95.
Hemispherx BioPharma (NYSE:HEB) last released its quarterly earnings data on Monday, August 14th. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter. Hemispherx BioPharma had a negative return on equity of 75.57% and a negative net margin of 1,029.58%. The company had revenue of $0.21 million for the quarter.
An institutional investor recently raised its position in Hemispherx BioPharma stock. Vanguard Group Inc. grew its stake in shares of Hemispherx BioPharma, Inc (NYSE:HEB) by 0.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 453,805 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,709 shares during the quarter. Vanguard Group Inc. owned approximately 1.56% of Hemispherx BioPharma worth $227,000 as of its most recent filing with the Securities and Exchange Commission.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2017/11/13/hemispherx-biopharma-inc-heb-short-interest-update.html.
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.
Receive News & Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.